INS and type 2 diabetes mellitus: As it was demonstrated that metformin, the first-line medication for the treatment of type 2 diabetes, could inhibit TDO2, a key enzyme in tryptophan metabolism [17], we assessed the potential impact of diabetes therapy (except insulin, as patients on insulin therapy were excluded) on KPm concentrations.